SK285766B6 - Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy - Google Patents

Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy Download PDF

Info

Publication number
SK285766B6
SK285766B6 SK1836-99A SK183699A SK285766B6 SK 285766 B6 SK285766 B6 SK 285766B6 SK 183699 A SK183699 A SK 183699A SK 285766 B6 SK285766 B6 SK 285766B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
dried
compound
drying
preparation
Prior art date
Application number
SK1836-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK183699A3 (en
Inventor
Joanne Broadhead
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285766(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of SK183699A3 publication Critical patent/SK183699A3/sk
Publication of SK285766B6 publication Critical patent/SK285766B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1836-99A 1997-07-11 1998-06-29 Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy SK285766B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (2)

Publication Number Publication Date
SK183699A3 SK183699A3 (en) 2000-07-11
SK285766B6 true SK285766B6 (sk) 2007-07-06

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1836-99A SK285766B6 (sk) 1997-07-11 1998-06-29 Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy

Country Status (36)

Country Link
US (1) US6130208A (is)
EP (1) EP1000079B1 (is)
JP (1) JP4950380B2 (is)
KR (1) KR100786654B1 (is)
CN (2) CN1263533A (is)
AR (1) AR013157A1 (is)
AT (1) ATE340801T1 (is)
AU (1) AU8362598A (is)
BR (1) BR9810703A (is)
CA (1) CA2295628C (is)
CY (1) CY1105805T1 (is)
CZ (1) CZ298110B6 (is)
DE (1) DE69836023T2 (is)
DK (1) DK1000079T3 (is)
EE (1) EE04119B1 (is)
ES (1) ES2273425T3 (is)
HK (1) HK1026429A1 (is)
HU (1) HU226489B1 (is)
ID (1) ID24716A (is)
IL (2) IL133868A0 (is)
IS (1) IS2439B (is)
MY (1) MY116421A (is)
NO (1) NO329918B1 (is)
NZ (1) NZ502073A (is)
PL (1) PL192768B1 (is)
PT (1) PT1000079E (is)
RU (1) RU2216330C2 (is)
SA (1) SA98190328B1 (is)
SE (1) SE9702680D0 (is)
SI (1) SI1000079T1 (is)
SK (1) SK285766B6 (is)
TR (1) TR200000006T2 (is)
TW (1) TW585764B (is)
UA (1) UA65576C2 (is)
WO (1) WO1999002542A1 (is)
ZA (1) ZA985669B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
WO2012079035A1 (en) * 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
US9700347B2 (en) 2011-08-17 2017-07-11 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
CN115120606A (zh) 2013-03-09 2022-09-30 奇斯药制品公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
BR112017014996A2 (pt) 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (is) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
DK0683789T3 (da) * 1993-02-10 1998-02-09 Astra Pharma Prod N-alkyl-2-substituerede ATP-analoger
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
CA2223921A1 (en) * 1995-06-07 1996-12-19 Francis C. Szoka, Jr. Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
CA2295628C (en) 2008-07-29
NO20000123D0 (no) 2000-01-10
CN1864696A (zh) 2006-11-22
KR20010021647A (ko) 2001-03-15
ES2273425T3 (es) 2007-05-01
TR200000006T2 (tr) 2000-07-21
SK183699A3 (en) 2000-07-11
NZ502073A (en) 2001-09-28
HU226489B1 (en) 2009-03-02
IL133868A0 (en) 2001-04-30
JP2001509512A (ja) 2001-07-24
UA65576C2 (uk) 2004-04-15
HUP0002622A2 (hu) 2001-05-28
PT1000079E (pt) 2006-12-29
DK1000079T3 (da) 2006-11-20
NO329918B1 (no) 2011-01-24
DE69836023D1 (de) 2006-11-09
TW585764B (en) 2004-05-01
DE69836023T2 (de) 2007-04-12
CZ200083A3 (cs) 2000-06-14
CY1105805T1 (el) 2011-02-02
SE9702680D0 (sv) 1997-07-11
KR100786654B1 (ko) 2007-12-21
HK1026429A1 (en) 2000-12-15
CZ298110B6 (cs) 2007-06-27
EE04119B1 (et) 2003-08-15
IS2439B (is) 2008-11-15
PL337970A1 (en) 2000-09-11
EE200000022A (et) 2000-10-16
ID24716A (id) 2000-08-03
ZA985669B (en) 1999-01-11
EP1000079A1 (en) 2000-05-17
WO1999002542A1 (en) 1999-01-21
CN1263533A (zh) 2000-08-16
BR9810703A (pt) 2000-08-08
PL192768B1 (pl) 2006-12-29
ATE340801T1 (de) 2006-10-15
CA2295628A1 (en) 1999-01-21
JP4950380B2 (ja) 2012-06-13
AR013157A1 (es) 2000-12-13
US6130208A (en) 2000-10-10
IS5331A (is) 1999-12-30
MY116421A (en) 2004-01-31
EP1000079B1 (en) 2006-09-27
SI1000079T1 (sl) 2007-08-31
AU8362598A (en) 1999-02-08
HUP0002622A3 (en) 2002-04-29
NO20000123L (no) 2000-03-03
SA98190328B1 (ar) 2006-08-15
RU2216330C2 (ru) 2003-11-20
IL133868A (en) 2010-05-17

Similar Documents

Publication Publication Date Title
SK285766B6 (sk) Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy
US5942510A (en) Pharmaceutical composition containing lamotrigine
RU2205012C2 (ru) Фармацевтические композиции для сушки вымораживанием
SK280840B6 (sk) Lyofilizovaný prípravok obsahujúci 1,1',1''-fosfinotioylidíntrisaziridín a spôsob jeho výroby
AU2003257524B2 (en) New formulation
MXPA00000100A (en) New formulation
MXPA99005664A (en) Pharmaceutical compositions for freeze drying

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180629